WO2002005776A1 - Composition, in particular cosmetic, containing dhea or some of its derivatives and a carotenoid - Google Patents

Composition, in particular cosmetic, containing dhea or some of its derivatives and a carotenoid Download PDF

Info

Publication number
WO2002005776A1
WO2002005776A1 PCT/FR2001/001789 FR0101789W WO0205776A1 WO 2002005776 A1 WO2002005776 A1 WO 2002005776A1 FR 0101789 W FR0101789 W FR 0101789W WO 0205776 A1 WO0205776 A1 WO 0205776A1
Authority
WO
WIPO (PCT)
Prior art keywords
dhea
composition according
composition
chosen
skin
Prior art date
Application number
PCT/FR2001/001789
Other languages
French (fr)
Inventor
Lionel Breton
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Priority to AU2001267620A priority Critical patent/AU2001267620A1/en
Publication of WO2002005776A1 publication Critical patent/WO2002005776A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to a composition containing at least one compound chosen from DHEA and / or a precursor or chemical or biological derivative thereof, and at least one carotenoid, as well as to the use of said composition, especially to prevent or treat the signs of actinic skin aging.
  • DHEA dehydroepiandrosterone
  • Exogenous DHEA administered topically or orally, is known for its ability to promote keratinization of the epidermis (JP-07 196 467) and to treat dry skin by increasing endogenous production and sebum secretion and by thus reinforcing the barrier effect of the skin (US-4,496,556).
  • the use of DHEA to remedy atrophy of the dermis by inhibiting the loss of collagen and connective tissue has also been described in US Pat. No. 5,843,932. It has also been described in US Pat. No. 5,736,537 the oral use of DHEA esters, in particular DHEA salicylate, for regulating the atrophy of the skin due to thinning or general degradation of the dermis.
  • the present invention therefore relates to a composition containing at least one compound chosen from DHEA and / or a precursor or chemical or biological derivative thereof, characterized in that it also comprises at least one non-provitamin A carotenoid. or a natural extract containing it.
  • DHEA has the following formula (I):
  • DHEA precursors is meant its biological precursors which are capable of transforming into DHEA during metabolism, as well as its chemical precursors which can transform into DHEA by exogenous chemical reaction.
  • biological precursors are ⁇ 5-pregnenolone, 17 ⁇ -hydroxy pregnenolone and 17 ⁇ -hydroxy pregnenolone sulfate, without this list being limiting.
  • Examples of chemical precursors are sapogenins and their derivatives, such as diosgenin (or spirost-5-en-3-beta-ol), hecogenin, hecogenin acetate, smilagenin and sarsapogenin, as well as the natural extracts containing it, in particular fenugreek and the extracts of Dioscorees such as the root of wild yam or Wild Yam, without this list being limiting.
  • diosgenin or spirost-5-en-3-beta-ol
  • hecogenin hecogenin acetate
  • smilagenin sarsapogenin
  • the natural extracts containing it in particular fenugreek and the extracts of Dioscorees such as the root of wild yam or Wild Yam, without this list being limiting.
  • DHEA derivatives is understood to mean both its biological derivatives and its chemical derivatives.
  • biological derivatives there may be mentioned in particular ⁇ 5-androstene-3,17-diol and ⁇ 4-androstene-3,17-dione, without this list being limiting.
  • chemical derivatives mention may in particular be made of DHEA salts, in particular water-soluble salts, such as DHEA sulfate.
  • esters such as the esters of hydroxycarboxylic acids and of DHEA described in particular in US Pat. No. 5,736,537 or the other esters such as salicylate, acetate, valerate (or n-heptanoate) and enanthate of DHEA.
  • DHEA derivatives DHEA carbamates, DHEA 2-hydroxy malonate esters and DHEA amino acid esters
  • DHEA amino acid esters DHEA carbamates, DHEA 2-hydroxy malonate esters and DHEA amino acid esters
  • DHEA analogues The precursors and chemical and biological derivatives of DHEA will hereinafter be called "DHEA analogues”.
  • the concentration of DHEA and / or the like in the composition according to the invention is advantageously between 0.00001% and 10% by weight, preferably between 0.0001% and 5% by weight, relative to the total weight of the composition.
  • composition according to the present invention contains, in combination with DHEA and / or its analogs, at least one non-provitamin A carotenoid.
  • non-provitamin A carotenoid examples include zeaxanthin, lutein, cryptoxanthin and lycopene, without this list being exhaustive. Lycopene is preferred for use in the present invention.
  • Lycopene is a natural pigment found in ripe fruit, especially in tomatoes.
  • the lycopene used according to the invention can be of natural or synthetic origin.
  • natural origin is meant lycopene, in the pure state or in solution whatever its concentration in said solution, obtained from a natural element such as for example a plant extract, particularly tomato.
  • synthetic origin is meant lycopene, in the pure state or in solution whatever its concentration in said solution, obtained by chemical synthesis.
  • lycopene When lycopene is of natural origin, it can be obtained from plant material obtained from a whole plant cultivated in vivo or from culture in vitro.
  • the term “in vivo culture” is intended to mean any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground.
  • the term “in vitro culture” means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant. The selection pressure imposed by the physico-chemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material which is available throughout the year unlike plants cultivated in vivo.
  • a plant derived from culture in vivo is used.
  • a tomato extract rich in lycopene is used.
  • Lycopene can be in alcoholic solution, in particular ethanolic. It can also be in the form of a hydroalcoholic solution in any proportion, or even in the form of a solution consisting of water and propylene glycol in any proportion. It can alternatively be in the form of a lipid or lipid-alcoholic extract.
  • a tomato extract rich in lycopene is used, prepared by the company Metaphar, marketed under the name LycOMato® consisting of an oleoresin extract containing 6% of pure lycopene.
  • the amount of extract usable according to the invention is of course a function of the desired effect and can therefore vary to a large extent.
  • lycopene can be used in the pure state in an amount representing from 10 "12 % to 20% of the total weight of the composition and preferably in an amount representing from 10 " 8 % to 10% of the total weight of the composition.
  • Lycopene is notably known as an anti-radical agent (JP-A-8-283136).
  • DHEA and / or its analogues themselves have an activity on the signs of skin aging and in particular the atrophy of the epidermis, the pigment spots, the appearance papery of the skin, wrinkles, sagging skin and dull complexion.
  • Lycopene is also known for its activity on 5 ⁇ -reducfases (JP-2940964). It is therefore useful, on the one hand, in the treatment of hyperseborrhea and, on the other hand, as a compound intended to prevent hair loss or to promote their regrowth, due to the involvement of these proteins in aforementioned phenomena. Without wishing to be bound by this theory, the Applicant therefore believes that the seborrhea inhibiting effect exerted by them. carotenoids could make it possible to counter the increase in seborrhea generally observed by topical application of DHEA to the skin, and thus to make the composition according to the invention suitable for oily skin.
  • composition according to the invention can be in all dosage forms normally used for topical application to the skin, in particular in the form of an aqueous or oily solution, of an oil-in-water or water-in-oil emulsion or multiple, of a silicone emulsion, of a microemulsion or nanoemulsion, of an aqueous or oily gel, of a liquid, pasty or solid anhydrous product, of an oil-dispersion in an aqueous phase in the presence of spherules, these spherules possibly being polymeric nanoparticles such as nanospheres and nanocapsules or, better still, lipid vesicles of ionic and / or nonionic type.
  • This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. or a gel. It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can be used as a care product and / or as a skin makeup product.
  • the composition of the invention may also contain the adjuvants usual in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, odor absorbers and coloring matter.
  • the quantities of these various adjuvants are those conventionally used in the fields considered, and by example from 0.01 to 20% of the total weight of the composition.
  • These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and / or into the nanoparticles.
  • These adjuvants, as well as their concentrations must be such that they do not harm the advantageous properties of the combination of active agents according to the invention.
  • the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition.
  • the fats, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration.
  • the emulsifier and the coemulsifier are preferably present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
  • oils and in particular mineral oils such as mineral oils (petroleum jelly oil), oils of vegetable origin (avocado oil, soybean oil), oils of animal origin (lanolin) can be used.
  • synthetic oils perhydrosqualene
  • silicone oils cyclomethicone
  • fluorinated oils perfluoropolyethers.
  • Fatty alcohols such as cetyl alcohol, fatty acids, waxes and gums and in particular silicone gums can also be used as fats.
  • emulsifiers and coemulsifiers which can be used in the invention, there may be mentioned, for example, fatty acid esters of polyethylene glycol such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate; fatty acid and polyol esters such as glyceryl stearate, sorbitan tristearate and oxyethylenated sorbitan stearates available under the trade names Tween® 20 or Tween® 60, for example; and their mixtures.
  • polyethylene glycol such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate
  • fatty acid and polyol esters such as glyceryl stearate, sorbitan tristearate and oxyethylenated sorbitan stearates available under the trade names Tween® 20 or Tween® 60, for example; and their mixtures.
  • hydrophilic gelling agents mention may be made in particular of carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, quote clays modified such as bentones, metal salts of fatty acids and hydrophobic silica.
  • carboxyvinyl polymers carboxyvinyl polymers
  • acrylic copolymers such as acrylate / alkyl acrylate copolymers
  • polyacrylamides polysaccharides
  • natural gums and clays and, as lipophilic gelling agents, quote clays modified such as bentones, metal salts of fatty acids and hydrophobic silica.
  • depigmentants and keratolytic and / or scaling agents can be used in particular
  • the active agents indicated above and / or the analogs of DHEA according to the invention can be incorporated into spherules, in particular ionic or nonionic vesicles and / or nanoparticles (nanocapsules and / or nanospheres) , so as to isolate them from each other in the composition.
  • the composition can be adapted for oral administration.
  • it can be in the form of syrups, suspensions, solutions, emulsions, capsules, granules or tablets, for example.
  • the daily doses of DHEA or analogues administered orally can be between 1 and 100 mg / day, preferably between 25 and 75 mg / day.
  • DHEA or the like is present in the composition according to the invention in an amount allowing its administration at a dose of between 50 and 100 mg / day, said dosage being carried out in one or more doses, with a unit dose of 50 mg. .
  • composition according to the invention comprises an effective amount of DHEA or the like and of carotenoid, sufficient to obtain the desired effect, and a physiologically acceptable medium.
  • composition according to the invention finds in particular an application in the prevention and treatment of the signs of skin aging, in particular of actinic aging.
  • the present invention therefore also relates to the cosmetic use of the composition mentioned above for preventing or treating the signs of aging. skin, in particular of actinic aging.
  • the composition according to the invention is thus preferably used:
  • the present invention also relates to the use of the composition mentioned above for manufacturing a preparation intended to attenuate pigmentation spots.
  • Soft capsules are prepared, conventionally for those skilled in the art, having the following composition:
  • a care cream oil-in-water emulsion having the following composition is prepared, conventionally for a person skilled in the art:

Abstract

The invention concerns a composition containing DHEA and/or a chemical or biological precursor or derivative thereof, characterised in that it further comprises at least a non-provitamin A carotenoid, which can in particular be selected among xanthophyll, lutein and lycopene. The invention also concerns cosmetic and dermatological uses of said composition, in particular for preventing or treating skin ageing symptoms.

Description

COMPOSITION, NOTAMMENT COSMETIQUE, RENFERMANT LA DHEA OU CERTAINES DE SES DERIVES, ET UN CAROTENOÏDECOMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA OR CERTAIN DERIVATIVES THEREOF, AND A CAROTENOID
La présente invention se rapporte à une composition renfermant au moins un composé choisi parmi la DHEA et/ou un précurseur ou dérivé chimique ou biologique de celle-ci, 5 et au moins un caroténoïde, ainsi qu'à l'utilisation de ladite composition, notamment pour prévenir ou traiter les signes du vieillissement cutané actinique.The present invention relates to a composition containing at least one compound chosen from DHEA and / or a precursor or chemical or biological derivative thereof, and at least one carotenoid, as well as to the use of said composition, especially to prevent or treat the signs of actinic skin aging.
La DHEA, ou déhydroépiandrostérone, est un stéroïde naturel produit essentiellement par les glandes corticosurrénales. La DHEA exogène, administrée par voie topique ou 0 orale, est connue pour sa capacité à promouvoir la kératinisation de l'épiderme (JP-07 196 467) et à traiter les peaux sèches en augmentant la production endogène et la sécrétion de sébum et en renforçant ainsi l'effet barrière de la peau (US-4,496,556). Il a également été décrit dans le brevet US-5,843,932 l'utilisation de la DHEA pour remédier à l'atrophie du derme par inhibition de la perte de collagène et de tissu 5 conjonctif. Il a en outre été décrit dans le brevet US-5,736,537 l'utilisation par voie orale d'esters de DHEA, en particulier du salicylate de DHEA, pour réguler l'atrophie de la peau due à un amincissement ou une dégradation générale du derme.DHEA, or dehydroepiandrosterone, is a natural steroid produced primarily by the adrenal cortex. Exogenous DHEA, administered topically or orally, is known for its ability to promote keratinization of the epidermis (JP-07 196 467) and to treat dry skin by increasing endogenous production and sebum secretion and by thus reinforcing the barrier effect of the skin (US-4,496,556). The use of DHEA to remedy atrophy of the dermis by inhibiting the loss of collagen and connective tissue has also been described in US Pat. No. 5,843,932. It has also been described in US Pat. No. 5,736,537 the oral use of DHEA esters, in particular DHEA salicylate, for regulating the atrophy of the skin due to thinning or general degradation of the dermis.
Or, il est apparu à la Demanderesse que l'association de la DHEA avec un 0 caroténoïde pouvait permettre de prévenir ou traiter plus efficacement les signes de vieillissement cutané, en particulier du vieillissement actinique ou photovieillissement.However, it appeared to the Applicant that the association of DHEA with a carotenoid 0 could make it possible to prevent or more effectively treat the signs of skin aging, in particular of actinic aging or photoaging.
La présente invention a donc pour objet une composition renfermant au moins un composé choisi parmi la DHEA et/ou un précurseur ou dérivé chimique ou biologique 5 de celle-ci, caractérisée en ce qu'elle comprend en outre au moins un caroténoïde non provitaminique A ou un extrait naturel en contenant.The present invention therefore relates to a composition containing at least one compound chosen from DHEA and / or a precursor or chemical or biological derivative thereof, characterized in that it also comprises at least one non-provitamin A carotenoid. or a natural extract containing it.
La DHEA a la formule (I) suivante :DHEA has the following formula (I):
Figure imgf000002_0001
0 Elle est par exemple disponible auprès de la société AKZO NOBEL. Par précurseurs de la DHEA, on entend ses précurseurs biologiques qui sont susceptibles de se transformer en DHEA au cours du métabolisme, ainsi que ses précurseurs chimiques qui peuvent se transformer en DHEA par réaction chimique exogène. Des exemples de précurseurs biologiques sont la Δ5-prégnénolone, la 17α- hydroxy prégnénolone et le sulfate de 17α-hydroxy prégnénolone, sans que cette liste soit limitative. Des exemples de précurseurs chimiques sont les sapogénines et leurs dérivés, tels que la diosgénine (ou spirost-5-èn-3-beta-ol), l'hécogénine, l'acétate d'hécogénine, le smilagénine et la sarsapogénine, ainsi que les extraits naturels en contenant, en particulier le fenugrec et les extraits de Dioscorees telles que la racine d'igname sauvage ou Wild Yam, sans que cette liste soit limitative.
Figure imgf000002_0001
0 It is for example available from the company AKZO NOBEL. By DHEA precursors is meant its biological precursors which are capable of transforming into DHEA during metabolism, as well as its chemical precursors which can transform into DHEA by exogenous chemical reaction. Examples of biological precursors are Δ5-pregnenolone, 17α-hydroxy pregnenolone and 17α-hydroxy pregnenolone sulfate, without this list being limiting. Examples of chemical precursors are sapogenins and their derivatives, such as diosgenin (or spirost-5-en-3-beta-ol), hecogenin, hecogenin acetate, smilagenin and sarsapogenin, as well as the natural extracts containing it, in particular fenugreek and the extracts of Dioscorees such as the root of wild yam or Wild Yam, without this list being limiting.
Par dérivés de la DHEA, on entend aussi bien ses dérivés biologiques que ses dérivés chimiques. Comme dérivés biologiques, on peut citer notamment le Δ5-androstène- 3,17-diol et la Δ4-androstène-3,17-dione, sans que cette liste soit limitative. Comme dérivés chimiques, on peut citer notamment les sels de DHEA, en particulier les sels hydrosolubles, tels que le sulfate de DHEA. On peut citer également les esters, tels que les esters d'acides hydroxycarboxyliques et de DHEA décrits notamment dans US-5,736,537 ou les autres esters tels que le salicylate, l'acétate, le valérate (ou n- heptanoate) et l'énanthate de DHEA. On peut également citer les dérivés de DHEA (carbamates de DHEA, esters de 2-hydroxy malonate de DHEA et esters d'amino- acides de DHEA) décrits dans la demande FR 00/03846 au nom de la Demanderesse. Cette liste n'est évidemment pas limitative.The term DHEA derivatives is understood to mean both its biological derivatives and its chemical derivatives. As biological derivatives, there may be mentioned in particular Δ5-androstene-3,17-diol and Δ4-androstene-3,17-dione, without this list being limiting. As chemical derivatives, mention may in particular be made of DHEA salts, in particular water-soluble salts, such as DHEA sulfate. Mention may also be made of esters, such as the esters of hydroxycarboxylic acids and of DHEA described in particular in US Pat. No. 5,736,537 or the other esters such as salicylate, acetate, valerate (or n-heptanoate) and enanthate of DHEA. Mention may also be made of the DHEA derivatives (DHEA carbamates, DHEA 2-hydroxy malonate esters and DHEA amino acid esters) described in application FR 00/03846 in the name of the Applicant. This list is obviously not exhaustive.
Les précurseurs et dérivés chimiques et biologiques de DHEA seront dénommés ci- après "analogues de DHEA".The precursors and chemical and biological derivatives of DHEA will hereinafter be called "DHEA analogues".
La concentration en DHEA et/ou analogues dans la composition selon l'invention est avantageusement comprise entre 0,00001% et 10%- en poids, de préférence entre 0,0001% et 5% en poids, par rapport au poids total de la composition.The concentration of DHEA and / or the like in the composition according to the invention is advantageously between 0.00001% and 10% by weight, preferably between 0.0001% and 5% by weight, relative to the total weight of the composition.
La composition selon la présente invention renferme, en association avec la DHEA et/ou ses analogues, au moins un caroténoïde non provitaminique A. Des exemples de tels caroténoïdes sont la zéaxanthine, la lutéine, la cryptoxanthine et le lycopene, sans que cette liste soit limitative. Le lycopene est préféré pour une utilisation dans la présente invention.The composition according to the present invention contains, in combination with DHEA and / or its analogs, at least one non-provitamin A carotenoid. Examples of such carotenoids are zeaxanthin, lutein, cryptoxanthin and lycopene, without this list being exhaustive. Lycopene is preferred for use in the present invention.
Le lycopene est un pigment naturel que l'on trouve dans les fruits mûrs, particulièrement dans la tomate.Lycopene is a natural pigment found in ripe fruit, especially in tomatoes.
Le lycopene utilisé selon l'invention peut être d'origine naturelle ou synthétique. Par origine naturelle, on entend le lycopene, à l'état pur ou en solution quelle qu'en soit sa concentration dans ladite solution, obtenu à partir d'un élément naturel comme par exemple un extrait végétal, particulièrement la tomate. Par origine synthétique, on entend le lycopene, à l'état pur ou en solution quelle qu'en soit sa concentration dans ladite solution, obtenu par synthèse chimique.The lycopene used according to the invention can be of natural or synthetic origin. By natural origin is meant lycopene, in the pure state or in solution whatever its concentration in said solution, obtained from a natural element such as for example a plant extract, particularly tomato. By synthetic origin is meant lycopene, in the pure state or in solution whatever its concentration in said solution, obtained by chemical synthesis.
Lorsque le lycopene est d'origine naturelle, il peut être obtenu à partir de matériel végétal issu de plante entière cultivée in vivo ou issu de culture in vitro. Par culture in vivo, on entend toute culture de type classique c'est-à-dire en sol à l'air libre ou en serre, ou encore hors sol. Par culture in vitro, on entend l'ensemble des techniques connues de l'homme du métier qui permet de manière artificielle l'obtention d'un végétal ou d'une partie d'un végétal. La pression de sélection imposée par les conditions physico-chimiques lors de la croissance des cellules végétales in vitro permet d'obtenir un matériel végétal standardisé et disponible tout au long de l'année contrairement aux plantes cultivées in vivo.When lycopene is of natural origin, it can be obtained from plant material obtained from a whole plant cultivated in vivo or from culture in vitro. The term “in vivo culture” is intended to mean any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground. The term “in vitro culture” means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant. The selection pressure imposed by the physico-chemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material which is available throughout the year unlike plants cultivated in vivo.
Preferentiellement selon l'invention, on utilise un végétal issu de culture in vivo. Très preferentiellement selon l'invention, on utilise un extrait de tomate riche en lycopene.Preferably according to the invention, a plant derived from culture in vivo is used. Very preferably according to the invention, a tomato extract rich in lycopene is used.
Toute méthode d'extraction connue de l'homme du métier peut être utilisée pour préparer le lycopene utilisé selon l'invention. Le lycopene peut être en solution alcoolique, notamment éthanolique. Il peut aussi se trouver sous forme de solution hydroalcoolique en toute proportion, ou encore sous forme de solution constituée d'eau et de propylène glycol en toute proportion. Il peut en variante se trouver sous forme d'un extrait lipidique ou lipido-alcoolique. A titre d'exemple, selon l'invention, on utilise un extrait de tomate riche en lycopene, préparé par la société Métaphar, commercialisé sous la dénomination LycOMato® constitué d'un extrait d'oléorésine contenant 6% de lycopene pur.Any extraction method known to a person skilled in the art can be used to prepare the lycopene used according to the invention. Lycopene can be in alcoholic solution, in particular ethanolic. It can also be in the form of a hydroalcoholic solution in any proportion, or even in the form of a solution consisting of water and propylene glycol in any proportion. It can alternatively be in the form of a lipid or lipid-alcoholic extract. By way of example, according to the invention, a tomato extract rich in lycopene is used, prepared by the company Metaphar, marketed under the name LycOMato® consisting of an oleoresin extract containing 6% of pure lycopene.
La quantité d'extrait utilisable selon l'invention est bien entendu fonction de l'effet recherché et peut donc varier dans une large mesure.The amount of extract usable according to the invention is of course a function of the desired effect and can therefore vary to a large extent.
Pour donner un ordre de grandeur, on peut utiliser le lycopene à l'état pur en une quantité représentant de 10"12 % à 20% du poids total de la composition et preferentiellement en une quantité représentant de 10"8 % à 10 % du poids total de la composition.To give an order of magnitude, lycopene can be used in the pure state in an amount representing from 10 "12 % to 20% of the total weight of the composition and preferably in an amount representing from 10 " 8 % to 10% of the total weight of the composition.
Bien entendu, l'homme du métier, s'il utilise le lycopene sous la forme d'une solution, un extrait végétal par exemple, sait ajuster la quantité de solution qu'il utilise dans sa composition afin que la quantité finale de lycopene dans la composition soit en accord avec les quantités utilisables précédemment définies.Of course, a person skilled in the art, if he uses lycopene in the form of a solution, a plant extract for example, knows how to adjust the amount of solution he uses in its composition so that the final amount of lycopene in the composition is in agreement with the usable quantities previously defined.
Le lycopene est notamment connu comme agent anti-radicalaire (JP-A-8-283136).Lycopene is notably known as an anti-radical agent (JP-A-8-283136).
Or, la Demanderesse a démontré que la DHEA et/ou ses analogues, appliqués par voie topique, ont eux-mêmes une activité sur les signes du vieillissement cutané et en particulier l'atrophie de l'épiderme, les taches pigmentaires, l'aspect papyracé de la peau, les rides, le relâchement cutané et le teint terne.However, the Applicant has demonstrated that DHEA and / or its analogues, applied topically, themselves have an activity on the signs of skin aging and in particular the atrophy of the epidermis, the pigment spots, the appearance papery of the skin, wrinkles, sagging skin and dull complexion.
On comprend donc que l'association de la DHEA et/ou de ses analogues avec des caroténoïdes permet de renforcer les effets anti-âge de la composition les contenant, en particulier lorsqu'il s'agit de prévenir ou traiter les signes du vieillissement cutané actinique.It is therefore understood that the combination of DHEA and / or its analogs with carotenoids makes it possible to reinforce the anti-aging effects of the composition containing them, in particular when it is a question of preventing or treating the signs of skin aging. actinic.
Le lycopene est également connu pour son activité sur les 5α-réducfases (JP-2940964). Il est donc utile, d'une part, dans le traitement de l'hyperséborrhée et, d'autre part, comme composé destiné à prévenir la chute des cheveux ou à favoriser leur repousse, en raison de l'implication de ces protéines dans les phénomènes précités. Sans vouloir être liée par cette théorie, la Demanderesse pense donc que l'effet inhibiteur de la séborrhée qu'exercent les. caroténoïdes pourrait permettre de contrer l'augmentation de la séborrhée généralement observée par application topique de la DHEA sur la peau, et de rendre ainsi la composition selon l'invention adaptée aux peaux grasses.Lycopene is also known for its activity on 5α-reducfases (JP-2940964). It is therefore useful, on the one hand, in the treatment of hyperseborrhea and, on the other hand, as a compound intended to prevent hair loss or to promote their regrowth, due to the involvement of these proteins in aforementioned phenomena. Without wishing to be bound by this theory, the Applicant therefore believes that the seborrhea inhibiting effect exerted by them. carotenoids could make it possible to counter the increase in seborrhea generally observed by topical application of DHEA to the skin, and thus to make the composition according to the invention suitable for oily skin.
Enfin, les effets bénéfiques des caroténoïdes sur les cheveux suggèrent qu'ils pourraient renforcer l'effet de la DHEA et/ou ses analogues dans des produits capillaires dans lesquels la DHEA est connue pour agir sur la canitie.Finally, the beneficial effects of carotenoids on the hair suggest that they could reinforce the effect of DHEA and / or its analogues in hair products in which DHEA is known to act on canities.
La composition selon l'invention peut se présenter sous toutes les formes galéniques normalement utilisées pour une application topique sur la peau, notamment sous forme d'une solution aqueuse ou huileuse, d'une emulsion huile-dans-eau ou eau- dans-huile ou multiple, d'une emulsion siliconee, d'une microemulsion ou nanoémulsion, d'un gel aqueux ou huileux, d'un produit anhydre liquide, pâteux ou solide, d'une dispersion-d'huile dans une phase aqueuse en présence de sphérules, ces sphérules pouvant être des nanoparticules polymériques telles que les nanosphères et les nanocapsules ou, mieux, des vésicules lipidiques de type ionique et/ou non-ionique.The composition according to the invention can be in all dosage forms normally used for topical application to the skin, in particular in the form of an aqueous or oily solution, of an oil-in-water or water-in-oil emulsion or multiple, of a silicone emulsion, of a microemulsion or nanoemulsion, of an aqueous or oily gel, of a liquid, pasty or solid anhydrous product, of an oil-dispersion in an aqueous phase in the presence of spherules, these spherules possibly being polymeric nanoparticles such as nanospheres and nanocapsules or, better still, lipid vesicles of ionic and / or nonionic type.
Cette composition peut être plus ou moins fluide et avoir l'aspect d'une crème blanche ou colorée, d'une pommade, d'un lait, d'une lotion, d'un sérum, d'une pâte, d'une mousse ou d'un gel. Elle peut éventuellement être appliquée sur la peau sous forme d'aérosol. Elle peut également se présenter sous forme solide, et par exemple sous forme de stick. Elle peut être utilisée comme produit de soin et/ou comme produit de maquillage de la peau.This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. or a gel. It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can be used as a care product and / or as a skin makeup product.
De façon connue, la composition de l'invention peut contenir également les adjuvants habituels dans les domaines cosmétique et dermatologique, tels que les gélifiants hydrophiles ou lipophiles, les actifs hydrophiles ou lipophiles, les conservateurs, les antioxydants, les solvants, les parfums, les charges, les filtres, les pigments, les absorbeurs d'odeur et les matières colorantes. Les quantités de ces différents adjuvants sont celles classiquement utilisées dans les domaines considérés, et par exemple de 0,01 à 20 % du poids total de la composition. Ces adjuvants, selon leur nature, peuvent être introduits dans la phase grasse, dans la phase aqueuse, dans les vésicules lipidiques et/ou dans les nanoparticules. Ces adjuvants, ainsi que leurs concentrations, doivent être tels qu'ils ne nuisent pas aux propriétés avantageuses de l'association d'actifs selon l'invention.In a known manner, the composition of the invention may also contain the adjuvants usual in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, odor absorbers and coloring matter. The quantities of these various adjuvants are those conventionally used in the fields considered, and by example from 0.01 to 20% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and / or into the nanoparticles. These adjuvants, as well as their concentrations, must be such that they do not harm the advantageous properties of the combination of active agents according to the invention.
Lorsque la composition selon l'invention est une emulsion, la proportion de la phase grasse peut aller de 5 à 80 % en poids, et de préférence de 5 à 50 % en poids par rapport au poids total de la composition. Les matières grasses, les émulsionnants et les coemulsionnants utilisés dans la composition sous forme d'émulsion sont choisis parmi ceux classiquement utilisés dans le domaine considéré. L'émulsionnant et le coémulsionnant sont de préférence présents, dans la composition, en une proportion allant de 0,3 à 30 % en poids, et de préférence de 0,5 à 20 % en poids par rapport au poids total de la composition.When the composition according to the invention is an emulsion, the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition. The fats, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration. The emulsifier and the coemulsifier are preferably present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
Comme matières grasses utilisables dans l'invention, on peut utiliser les huiles et notamment les huiles minérales (huile de vaseline), les huiles d'origine végétale (huile d'avocat, huile de soja), les huiles d'origine animale (lanoline), les huiles de synthèse (perhydrosqualène), les huiles siliconées (cyclométhicone) et les huiles fluorées (perfluoropolyethers). On peut aussi utiliser comme matières grasses des alcools gras tels que l'alcool cétylique, des acides gras, des cires et des gommes et en particulier les gommes de silicone.As fats which can be used in the invention, oils and in particular mineral oils (petroleum jelly oil), oils of vegetable origin (avocado oil, soybean oil), oils of animal origin (lanolin) can be used. ), synthetic oils (perhydrosqualene), silicone oils (cyclomethicone) and fluorinated oils (perfluoropolyethers). Fatty alcohols such as cetyl alcohol, fatty acids, waxes and gums and in particular silicone gums can also be used as fats.
Comme émulsionnants et coemulsionnants utilisables dans l'invention, on peut citer par exemple les esters d'acide gras et de polyethylène glycol tels que le stéarate de PEG-100, le stéarate de PEG-50 et le stéarate de PEG-40 ; les esters d'acide gras et de polyol tels que le stéarate de glycéryle, le tristéarate de sorbitane et les stéarates de sorbitane oxyéthylénés disponibles sous les dénominations commerciales Tween® 20 ou Tween® 60, par exemple ; et leurs mélanges.As emulsifiers and coemulsifiers which can be used in the invention, there may be mentioned, for example, fatty acid esters of polyethylene glycol such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate; fatty acid and polyol esters such as glyceryl stearate, sorbitan tristearate and oxyethylenated sorbitan stearates available under the trade names Tween® 20 or Tween® 60, for example; and their mixtures.
Comme gélifiants hydrophiles, on peut citer en particulier les polymères carboxyvinyliques (carbomer), les copolymères acryliques tels que les copolymères d'acrylates/alkylacrylates, les polyacrylamides, les polysaccharides, les gommes naturelles et les argiles, et, comme gélifiants lipophiles, on peut citer les argiles modifiées comme les bentones, les sels métalliques d'acides gras et la silice hydrophobe.As hydrophilic gelling agents, mention may be made in particular of carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, quote clays modified such as bentones, metal salts of fatty acids and hydrophobic silica.
Comme actifs, on peut utiliser notamment les dépigmentants et les agents kératolytiques et/ou desquamantsAs active agents, depigmentants and keratolytic and / or scaling agents can be used in particular
En cas d'incompatibilité, les actifs indiqués ci-dessus et/ou les analogues de DHEA selon l'invention peuvent être incorporés dans des sphérules, notamment des vésicules ioniques ou non-ioniques et/ou des nanoparticules (nanocapsules et/ou nanosphères), de manière à les isoler les uns des autres dans la composition.In the event of incompatibility, the active agents indicated above and / or the analogs of DHEA according to the invention can be incorporated into spherules, in particular ionic or nonionic vesicles and / or nanoparticles (nanocapsules and / or nanospheres) , so as to isolate them from each other in the composition.
Selon une variante de l'invention, la composition peut être adaptée à une administration par voie orale. Dans ce cas, elle peut se présenter sous forme de sirops, de suspensions, de solutions, d'émulsions, de capsules, de granules ou de comprimés, par exemple.According to a variant of the invention, the composition can be adapted for oral administration. In this case, it can be in the form of syrups, suspensions, solutions, emulsions, capsules, granules or tablets, for example.
Les doses quotidiennes de DHEA ou analogues administrées par voie orale peuvent être comprises entre 1 et 100 mg/jour, de préférence entre 25 et 75 mg/jour. Preferentiellement, la DHEA ou analogue est présente dans la composition selon l'invention en une quantité permettant son administration à une dose comprise entre 50 et 100 mg/jour, ladite posologie étant réalisée en une ou plusieurs prises, avec une dose unitaire de 50 mg.The daily doses of DHEA or analogues administered orally can be between 1 and 100 mg / day, preferably between 25 and 75 mg / day. Preferably, DHEA or the like is present in the composition according to the invention in an amount allowing its administration at a dose of between 50 and 100 mg / day, said dosage being carried out in one or more doses, with a unit dose of 50 mg. .
Dans tous les cas, la composition selon l'invention comprend une quantité efficace de DHEA ou analogue et de caroténoïde, suffisante pour obtenir l'effet recherché, et un milieu physiologiquement acceptable.In all cases, the composition according to the invention comprises an effective amount of DHEA or the like and of carotenoid, sufficient to obtain the desired effect, and a physiologically acceptable medium.
La composition selon l'invention trouve en particulier une application dans la prévention et le traitement des signes du vieillissement cutané, en particulier du vieillissement actinique.The composition according to the invention finds in particular an application in the prevention and treatment of the signs of skin aging, in particular of actinic aging.
La présente invention concerne donc également l'utilisation cosmétique de la composition mentionnée ci-dessus pour prévenir ou traiter les signes du vieillissement cutané, en particulier du vieillissement actinique. La composition selon l'invention est ainsi de préférence utilisée :The present invention therefore also relates to the cosmetic use of the composition mentioned above for preventing or treating the signs of aging. skin, in particular of actinic aging. The composition according to the invention is thus preferably used:
- pour prévenir ou réduire l'aspect papyracé de la peau, et/ou - pour améliorer l'homogénéité de la couleur de la peau et/ou pour blanchir la peau et/ou raviver l'éclat du teint, et/ou- to prevent or reduce the papery appearance of the skin, and / or - to improve the uniformity of the color of the skin and / or to whiten the skin and / or revive the radiance of the complexion, and / or
- pour traiter les rides et ridules, et/ou- to treat fine lines and wrinkles, and / or
- pour lutter contre le relâchement cutané, et/ou- to combat sagging skin, and / or
- pour lutter contre ou prévenir l'atrophie de l'épiderme.- to fight against or prevent atrophy of the epidermis.
La présente invention concerne également l'utilisation de la composition mentionnée ci-dessus pour fabriquer une préparation destinée à atténuer les taches pigmentaires.The present invention also relates to the use of the composition mentioned above for manufacturing a preparation intended to attenuate pigmentation spots.
Elle concerne aussi l'utilisation cosmétique de cette composition pour le traitement du cuir chevelu.It also relates to the cosmetic use of this composition for the treatment of the scalp.
L'invention sera maintenant illustrée par les exemples non limitatifs suivants. Dans ces exemples, les quantités sont indiquées en pourcentage pondéral.The invention will now be illustrated by the following nonlimiting examples. In these examples, the quantities are indicated in percentage by weight.
Exemple 1 - Composition pour administration oraleExample 1 Composition for Oral Administration
On prépare, de manière classique pour l'homme du métier, des capsules molles ayant la composition suivante :Soft capsules are prepared, conventionally for those skilled in the art, having the following composition:
Huile de soja hydrogénée 40 mgHydrogenated soybean oil 40 mg
Huile de blé 95 mgWheat oil 95 mg
Lécithine de soja 20 mgSoy lecithin 20 mg
Tocophérols naturels 5.mgNatural Tocopherols 5.mg
Acide ascorbique 30 mg Lycopene à 6 % 175 mgAscorbic acid 30 mg Lycopene 6% 175 mg
(Correspondant à environ 10 mg de lycopene)(Corresponding to approximately 10 mg of lycopene)
DHEA 50 mg Exemple 2 -Composition pour application topiqueDHEA 50 mg Example 2 -Composition for topical application
On prépare, de manière classique pour l'homme du métier, une crème de soin (emulsion huile dans eau) ayant la composition suivante :A care cream (oil-in-water emulsion) having the following composition is prepared, conventionally for a person skilled in the art:
Lycopene à 6 % 10"4 %Lycopene 6% 10 "4 %
DHEA 0,1 %DHEA 0.1%
Stéarate de glycérol 2 %2% glycerol stearate
Polysorbate 60 (Tween 60 ® vendu par la société ICI) 1 % Acide stearique 1,4 %Polysorbate 60 (Tween 60 ® sold by ICI) 1% Stearic acid 1.4%
Triethanolamine 0,7 %Triethanolamine 0.7%
Carbomer 0,4 %Carbomer 0.4%
Fraction liquide de beurre de karité 12 %Liquid fraction of shea butter 12%
Perhydrosqualène 12 % Parfum 0,5 %Perhydrosqualene 12% Perfume 0.5%
Conservateur QSQS Curator
Eau QSP 100 % 100% QSP water

Claims

REVENDICATIONS
1. Composition renfermant au moins un composé choisi parmi la DHEA et/ou un précurseur ou dérivé chimique ou biologique de celle-ci, caractérisée en ce qu'elle comprend en outre au moins un caroténoïde non provitaminique A ou un extrait naturel en contenant.1. Composition containing at least one compound chosen from DHEA and / or a precursor or chemical or biological derivative thereof, characterized in that it also comprises at least one non-provitamin A carotenoid or a natural extract containing it.
2. Composition selon la revendication 1 , caractérisée en ce que ledit précurseur chimique de la DHEA est choisi parmi les sapogénines et leurs dérivés, et les extraits naturels en contenant.2. Composition according to claim 1, characterized in that said chemical precursor of DHEA is chosen from sapogenins and their derivatives, and natural extracts containing them.
3. Composition selon la revendication 2, caractérisée en ce que ledit précurseur chimique est choisi parmi la diosgénine, l'hécogénine, l'acétate d'hécogénine, le smilagénine et la sarsapogénine.3. Composition according to claim 2, characterized in that said chemical precursor is chosen from diosgenin, hecogenin, hecogenin acetate, smilagenin and sarsapogenin.
4. Composition selon la revendication 2, caractérisée en ce que ledit extrait naturel est choisi parmi le fenugrec et les extraits de Dioscorees.4. Composition according to claim 2, characterized in that said natural extract is chosen from fenugreek and extracts from Dioscorees.
5. Composition selon la revendication 4, caractérisée en ce que ledit extrait de Dioscorée est un extrait de racine d'igname sauvage.5. Composition according to claim 4, characterized in that said extract of Dioscorea is an extract of wild yam root.
6. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce que ledit précurseur biologique est choisi parmi : la Δ5-prégnénolone, la 17α- hydroxy prégnénolone et le sulfate de 17α-hydroxy prégnénolone.6. Composition according to any one of the preceding claims, characterized in that said biological precursor is chosen from: Δ5-pregnenolone, 17α-hydroxy pregnenolone and 17α-hydroxy pregnenolone sulfate.
7. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce que ledit dérivé biologique est choisi parmi : le Δ5-androstène-3,17-diol et la Δ4- androstène-3, 17-dione.7. Composition according to any one of the preceding claims, characterized in that the said biological derivative is chosen from: Δ5-androstene-3,17-diol and Δ4-androstene-3, 17-dione.
8. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce que ledit dérivé chimique est choisi parmi : les sels de DHEA et les esters de DHEA. 8. Composition according to any one of the preceding claims, characterized in that the said chemical derivative is chosen from: DHEA salts and DHEA esters.
9. Composition. selon la revendication 8, caractérisée en ce que ledit sel de DHEA est choisi parmi les sels hydrosolubles, tels que le sulfate de DHEA.9. Composition . according to claim 8, characterized in that said DHEA salt is chosen from water-soluble salts, such as DHEA sulfate.
10. Composition selon la revendication 8, caractérisée en ce que ledit ester de DHEA est choisi parmi : les esters d'acides hydroxycarboxyliques et de DHEA ; le salicylate de DHEA ; l'acétate de DHEA ; le valérate de DHEA ; et l'énanthate de DHEA.10. Composition according to claim 8, characterized in that said DHEA ester is chosen from: esters of hydroxycarboxylic acids and DHEA; DHEA salicylate; DHEA acetate; DHEA valerate; and DHEA enanthate.
11. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle renferme de 0,0001 à 5% en poids de DHEA et/ou précurseur ou dérivé, par rapport au poids total de la composition.11. Composition according to any one of the preceding claims, characterized in that it contains from 0.0001 to 5% by weight of DHEA and / or precursor or derivative, relative to the total weight of the composition.
12. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce que ledit caroténoïde est choisi parmi la zéaxanthine, la lutéine, la cryptoxanthine et le lycopene.12. Composition according to any one of the preceding claims, characterized in that the said carotenoid is chosen from zeaxanthin, lutein, cryptoxanthin and lycopene.
13. Composition selon la revendication 12, caractérisée en ce que ledit caroténoïde est le lycopene.13. Composition according to claim 12, characterized in that said carotenoid is lycopene.
14. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle comprend de 10"8% à 10% en poids de caroténoïde, par rapport au poids total de la composition.14. Composition according to any one of the preceding claims, characterized in that it comprises from 10 "8 % to 10% by weight of carotenoid, relative to the total weight of the composition.
15. Utilisation cosmétique de la composition selon l'une quelconque des revendications précédentes pour prévenir ou traiter les signes du vieillissement cutané, en particulier du vieillissement actinique.15. Cosmetic use of the composition according to any one of the preceding claims for preventing or treating the signs of skin aging, in particular of actinic aging.
16. Utilisation cosmétique de la composition selon l'une quelconque des revendications 1 à 14 pour prévenir ou réduire l'aspect papyracé de la peau et/ou pour améliorer l'homogénéité de la couleur de la peau et/ou pour blanchir la peau et/ou raviver l'éclat du teint, et/ou pour traiter les rides et ridules et/ou pour lutter contre le relâchement cutané, et/ou pour lutter contre ou prévenir l'atrophie de l'épiderme.16. Cosmetic use of the composition according to any one of claims 1 to 14 for preventing or reducing the papery appearance of the skin and / or for improving the uniformity of the color of the skin and / or for whitening the skin and / or revive the radiance of the complexion, and / or to treat fine lines and wrinkles and / or to combat sagging skin, and / or to combat or prevent atrophy of the epidermis.
17. Utilisation de la composition selon l'une quelconque des revendications 1 à 14 pour fabriquer une préparation destinée à atténuer les taches pigmentaires. 17. Use of the composition according to any one of claims 1 to 14 for manufacturing a preparation intended to attenuate pigmentation spots.
8. Utilisation cosmétique de la composition selon l'une quelconque des revendications à 14 pour le traitement du cuir chevelu. 8. Cosmetic use of the composition according to any one of claims to 14 for the treatment of the scalp.
REVENDICATIONS MODIFIEESAMENDED CLAIMS
[reçues par le Bureau international le 16 novembre 2001 (16.11.01); revendications 1-18 remplacées par les revendications 1-12 modifiées (2 pages)][received by the International Bureau on November 16, 2001 (16.11.01); claims 1-18 replaced by amended claims 1-12 (2 pages)]
1. Composition renfermant au moins un composé choisi parmi la DHEA et/ou une sapogenine et/ou un dérivé de sapogenine et/ou un extrait naturel contenant une sapogenine, caractérisée en ce qu'elle comprend en outre au moins un caroténoïde non provitaminique A ou un extrait naturel en contenant.1. Composition containing at least one compound chosen from DHEA and / or a sapogenin and / or a sapogenin derivative and / or a natural extract containing a sapogenin, characterized in that it also comprises at least one non-provitamin A carotenoid or a natural extract containing it.
2. Composition selon la revendication 1 , caractérisée en ce que ladite sapogenine est choisie parmi la diosgénine, l'hécogénine, , la smilagénine et la sarsapogénine.2. Composition according to claim 1, characterized in that said sapogenin is chosen from diosgenin, hecogenin, smilagenin and sarsapogenin.
3. Composition selon la revendication 1 , caractérisée en ce que ledit extrait naturel est choisi parmi le fenugrec et les extraits de Dioscorees.3. Composition according to claim 1, characterized in that said natural extract is chosen from fenugreek and extracts from Dioscorees.
4. Composition selon la revendication 3, caractérisée en ce que ledit extrait de Dioscorée est un extrait de racine d'igname sauvage.4. Composition according to claim 3, characterized in that said Dioscorea extract is an extract of wild yam root.
5. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle renferme de 0,0001 à 5% en poids de DHEA et/ou sapogenine et/ou dérivé de sapogenine et/ou extrait contenant une sapogenine, par rapport au poids total de la composition.5. Composition according to any one of the preceding claims, characterized in that it contains from 0.0001 to 5% by weight of DHEA and / or sapogenin and / or sapogenin derivative and / or extract containing a sapogenin, relative the total weight of the composition.
6. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce que ledit caroténoïde est choisi parmi la zéaxanthine, la lutéine, la cryptoxanthine et le lycopene.6. Composition according to any one of the preceding claims, characterized in that said carotenoid is chosen from zeaxanthin, lutein, cryptoxanthin and lycopene.
7. Composition selon la revendication 6, caractérisée en ce que ledit caroténoïde est le lycopene.7. Composition according to claim 6, characterized in that said carotenoid is lycopene.
8. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle comprend de 10"8% à 10% en poids de caroténoïde, par rapport au poids total de la composition.8. Composition according to any one of the preceding claims, characterized in that it comprises from 10 "8 % to 10% by weight of carotenoid, relative to the total weight of the composition.
9. Utilisation cosmétique d'une composition renfermant au moins un composé choisi parmi la DHEA et/ou un précurseur ou dérivé chimique ou biologique de celle-ci pour prévenir ou traiter les signes du vieillissement cutané, en particulier du vieillissement actinique.9. Cosmetic use of a composition containing at least one compound chosen from DHEA and / or a precursor or chemical or biological derivative thereof for prevent or treat the signs of skin aging, in particular actinic aging.
10. Utilisation cosmétique d'une composition renfermant au moins un composé choisi parmi la DHEA et/ou un précurseur ou dérivé chimique ou biologique de celle-ci pour prévenir ou réduire l'aspect papyracé de la peau et/ou pour améliorer l'homogénéité de la couleur de la peau et/ou pour blanchir la peau et/ou raviver l'éclat du teint, et/ou pour traiter les rides et ridules et/ou pour lutter contre le relâchement cutané, et/ou pour lutter contre ou prévenir l'atrophie de l'épiderme.10. Cosmetic use of a composition containing at least one compound chosen from DHEA and / or a precursor or chemical or biological derivative thereof to prevent or reduce the papery appearance of the skin and / or to improve homogeneity skin color and / or to whiten the skin and / or revive the radiance of the complexion, and / or to treat fine lines and wrinkles and / or to combat sagging skin, and / or to combat or prevent atrophy of the epidermis.
11. Utilisation d'une composition renfermant au moins un composé choisi parmi la DHEA et/ou un précurseur ou dérivé chimique ou biologique de celle-ci pour fabriquer une préparation destinée à atténuer les taches pigmentaires.11. Use of a composition containing at least one compound chosen from DHEA and / or a precursor or chemical or biological derivative thereof for producing a preparation intended to attenuate pigmentary spots.
12. Utilisation cosmétique de la composition selon l'une quelconque des revendications 1 à 8 pour le traitement du cuir chevelu. 12. Cosmetic use of the composition according to any one of claims 1 to 8 for the treatment of the scalp.
PCT/FR2001/001789 2000-07-13 2001-06-08 Composition, in particular cosmetic, containing dhea or some of its derivatives and a carotenoid WO2002005776A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001267620A AU2001267620A1 (en) 2000-07-13 2001-06-08 Composition, in particular cosmetic, containing dhea or some of its derivatives and a carotenoid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0009233A FR2811569B1 (en) 2000-07-13 2000-07-13 COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND / OR ITS PRECURSORS OR DERIVATIVES, AND A CAROTENOID
FR00/09233 2000-07-13

Publications (1)

Publication Number Publication Date
WO2002005776A1 true WO2002005776A1 (en) 2002-01-24

Family

ID=8852495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/001789 WO2002005776A1 (en) 2000-07-13 2001-06-08 Composition, in particular cosmetic, containing dhea or some of its derivatives and a carotenoid

Country Status (3)

Country Link
AU (1) AU2001267620A1 (en)
FR (1) FR2811569B1 (en)
WO (1) WO2002005776A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060729A1 (en) * 2008-11-03 2010-06-03 Giuliani S.P.A. Therapeutic, dietary, or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds
US10456344B2 (en) 2014-12-22 2019-10-29 Conopco, Inc. Hair composition

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2838344B1 (en) * 2002-04-12 2005-06-17 Oreal USE OF A SAPOGENINE, OR A NATURAL EXTRACT CONTAINING, TO ENHANCE THE RIDES AND RIDULES OF EXPRESSION

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003170A1 (en) * 1996-07-24 1998-01-29 Biosytes Usa, Inc. Method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same
WO2000000186A1 (en) * 1998-06-30 2000-01-06 American Medical Research, Inc. Method of treating topical ailments
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
JP2000191459A (en) * 1998-12-25 2000-07-11 Lion Corp Hair growth suppressor and cosmetic
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
WO1998003170A1 (en) * 1996-07-24 1998-01-29 Biosytes Usa, Inc. Method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
WO2000000186A1 (en) * 1998-06-30 2000-01-06 American Medical Research, Inc. Method of treating topical ailments
JP2000191459A (en) * 1998-12-25 2000-07-11 Lion Corp Hair growth suppressor and cosmetic

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 2000-545818, XP002168478 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060729A1 (en) * 2008-11-03 2010-06-03 Giuliani S.P.A. Therapeutic, dietary, or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds
CN102202659A (en) * 2008-11-03 2011-09-28 朱利亚尼股份公司 Therapeutic, dietary, or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds
US8729033B2 (en) 2008-11-03 2014-05-20 Giuliani S.P.A. Therapeutic, dietary or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds
US10456344B2 (en) 2014-12-22 2019-10-29 Conopco, Inc. Hair composition

Also Published As

Publication number Publication date
FR2811569B1 (en) 2003-03-14
AU2001267620A1 (en) 2002-01-30
FR2811569A1 (en) 2002-01-18

Similar Documents

Publication Publication Date Title
EP1090628B1 (en) Use of lycopene in compositions for treating ageing skin symptoms
FR2825277A1 (en) COSMETIC AND / OR DERMATOLOGICAL AND / OR PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE ENZIME 3, B-HSD IHNIBITOR COMPOUND
WO2002005775A1 (en) Composition, in particular cosmetic, containing dhea and/or a chemical or biological precursor or derivative thereof, and a metalloproteinase inhibitor
FR2817747A1 (en) USE OF AT LEAST ONE SAPOGENIN, OR A NATURAL EXTRACT CONTAINING SAME, TO PREVENT THE SIGNS OF SKIN AGING
WO2001082940A1 (en) Plant extract of the olea europaea species as no-synthase inhibitor and uses
EP0673238B1 (en) Use of a simarouba extract to reduce patchy skin pigmentation
EP1278508A1 (en) Plant extract of the species i vitis vinifera /i as no-synthase inhibitor and uses
EP1172094B1 (en) Composition, particularly for cosmetics, comprising DHEA and/or precursor or derivative, and at least a compound which increases the synthesis of glycosaminoglycans
EP1331924B1 (en) Use of beta-carotene and lycopene for treating ageing symptoms via the inhibition of the expression of the metalloproteinase of type 1 of the extracellular matrix
WO2002005778A1 (en) Composition, in particular cosmetic, comprising dhea and/or a precursor or derivative thereof, combined with at least a no-synthase inhibitor
EP1250121B1 (en) Use of dehydroepiandrosterone and/or precursors or derivatives thereof to improve papery aspect of the skin
EP1303253B1 (en) Composition, in particular cosmetic, comprising dhea and/or a precursor or derivative thereof, combined with at least a glycation inhibiting agent
FR2811562A1 (en) COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND AN ISOFLAVONOID
WO2015082520A1 (en) Composition for reducing skin ageing disorders, comprising a retinaldehyde and a leontopodium alpinum extract
WO2002005776A1 (en) Composition, in particular cosmetic, containing dhea or some of its derivatives and a carotenoid
WO2002034210A2 (en) Use of the association of at least a carotenoid and vitamin c for treating cutaneous symptoms of ageing
EP1343467A1 (en) Composition containing 7-hydroxy dhea and/or 7-keto dhea and at least a carotenoid
WO2002005779A1 (en) Composition, in particular cosmetic, containing dhea and/or its precursors or derivatives, and a vitamin
FR2815863A1 (en) COMPOSITION COMPRISING THE ASSOCIATION OF AT LEAST ONE EXTRACT OF AT LEAST ONE PLANT OF THE GENUS ROSMARINUS AND AT LEAST ONE CAROTENOID
WO2002047648A1 (en) Composition, in particular cosmetic, comprising 7-hydroxy dhea and/or 7-keto dhea and at least an anti-glycation agent
WO2002047655A1 (en) Composition, in particular cosmetic, comprising 7-hydroxy dhea or 7-keto dhea and at least a no-synthase inhibitor
WO2016198756A1 (en) Cosmetic, nutraceutical, veterinary and pharmaceutical compositions containing a hazelnut pericarp extract
WO2002034228A1 (en) Cosmetic composition comprising dhea and at least a muscle relaxant
FR2818137A1 (en) COMPOSITION, IN PARTICULAR COSMETIC, CONTAINING 7-HYDROXY DHEA AND / OR 7-KETO DHEA AND AT LEAST ONE VITAMIN AND / OR ENZYMATIC CO-FACTOR

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP